MSB (ASX) banter and General Discussion

MSB

Click for more information

3.21%

$1.13 mesoblast limited

First 10233 Last

Share
Profile

Follow
Fastback6666

2,033 Posts.

724

18/07/24

00:01

Post #: 74803106
Share

Originally posted by JB1975: ↑

The baseline level is a different number for each patient - it is a number but it could be 10,000 activated T cells per some small unit volume or blood weight of cell count for patient A and 9,000 activated T cells per whatever for patient B and so on.

So a 50% reduction after 28 days for patient A is a T cell count that is half what it was previously for patient A and the same for patient B.

Zero reduction and 100 percent reduction is the range you can't have a more than total reduction of the activated T cells which would be 100% reduction and you can't have less than no reduction.

I think you are interested in can the activated T cells actually go up such that rather than a reduction there would actually be an increase after 28 days? Well in healthy patients that didn't have a lot of activated T cells sure if they happened to be fighting an infection 28 days later that they didnt have before their T cells would be up - but that isn't the starting position here - because if the patients didn't already have relatively high T cell activation levels that would mean the T cells from the graft in their blood weren't actually attacking the host and so you wouldn't have GVHD in the first place.

When you are measuring T cell activation you are specifically measuring T cell based immunity specifically not inflammation. While inflammation and immunity can occur together they aren't the same. Other types of cells would be involved in inflammation.

The T cells are activated (in GVHD its believed) because they think they've encountered a foreign protein (a piece of the host cells that is only about 7 to 9 amino acids long - but those little pieces would be specific enough that the T cells from the graft responding to the foreign to them proteins that were proteins natural to the host but would not have been foreign to the graft that the T cells has come from.

This is not a perfect explanation but I believe its pretty accurate.

Expand

MSB Price at posting: $1.13 Sentiment: Buy Disclosure: Held
10 Upvote

3 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

The market's shrugged at China's stimulus measures all year. Why is this one different?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

There are more pages in this discussion • 825 more messages in this thread...

First 10233 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
2	27197	1.105
8	87146	1.100
2	71941	1.095
2	33264	1.090
2	18897	1.085

Price($)	Vol.	No.
1.125	43578	3
1.130	87126	8
1.135	1090	1
1.140	141598	9
1.145	64500	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Zeta Resources seeks to resolve the Panoramic takeover story

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

The market's shrugged at China's stimulus measures all year. Why is this one different?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Zeta Resources seeks to resolve the Panoramic takeover story

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News